院外心脏骤停伴难治性室颤患者的早期体外心肺复苏与标准ACLS随机对照试验(ARREST)
ARREST为美国单中心、开放标签、适应性2期RCT,纳入30例18-75岁院外心脏骤停伴难治性室颤(三次电击后无自主循环恢复、使用LUCAS自动心肺复苏、预计转运时间<30分钟)患者,随机分入早期ECMO辅助复苏组或标准ACLS组。因后验概率超过预设监测边界,研究在第一次期中分析时提前终止。6个月累积生存ECMO组显著优于标准ACLS组,未观察到非预期严重不良事件。
要点
- 纳入标准为18-75岁院外心脏骤停伴难治性室颤,三次电击后无自主循环恢复,使用LUCAS自动心肺复苏,预计转运时间<30分钟。
- 6个月累积生存ECMO组显著优于标准ACLS组;未观察到非预期严重不良事件。
- 该研究为单中心2期试验,样本量小(30例),结果需多中心验证。
适用人群与场景
- 成人18-75岁院外心脏骤停伴难治性室颤,三次电击后无自主循环恢复,使用LUCAS自动心肺复苏,预计转运至明尼苏达大学医学中心时间<30分钟。
- 排除标准:原文未提及具体排除标准,仅提及36例评估中排除6例后30例随机。
诊断标准与关键阈值
- 难治性室颤定义:院外心脏骤停伴室颤,三次电击后无自主循环恢复。
- 纳入需使用Lund University Cardiac Arrest System(LUCAS)自动心肺复苏,且预计转运时间<30分钟。
处置流程与药物剂量
- 第一步:院外心脏骤停伴难治性室颤患者,经三次电击无自主循环恢复,使用LUCAS自动心肺复苏,预计转运时间<30分钟。
- 第二步:到达医院后随机分配至早期ECMO辅助复苏或标准ACLS治疗。
- 第三步:早期ECMO辅助复苏组接受ECMO辅助复苏;标准ACLS组接受标准ACLS治疗(具体ACLS方案原文未提及)。
- 原文未提及ECMO具体参数、抗凝方案、药物剂量。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:2期、单中心、开放标签、适应性、安全性与有效性RCT;样本量30例(ECMO组15例,标准ACLS组15例,ECMO组1例出院前退出,分析14例);单中心(美国明尼苏达大学医学中心)。
- 人群:18-75岁院外心脏骤停伴难治性室颤,平均年龄59岁(范围36-73),男性25/30(83%)。
- 干预与对照:早期ECMO辅助复苏 vs 标准ACLS治疗,意向性分析。
- 关键次要终点:6个月累积生存ECMO组显著优于标准ACLS组;未观察到非预期严重不良事件。
- 研究因后验概率超过预设监测边界,在第一次期中分析(30例)时被NIH/NHLBI提前终止。
证据类型、等级与局限
- 证据类型:2期、单中心、开放标签、适应性RCT。
- 证据等级或推荐强度:原文未提及。
- 局限:单中心、样本量小(30例)、开放标签、提前终止、ECMO组1例退出、除外标准未详细列出、结果需多中心验证。
对床旁实践的改变
- 对符合纳入标准(18-75岁、院外心脏骤停伴难治性室颤、三次电击无自主循环恢复、LUCAS自动心肺复苏、预计转运时间<30分钟)的患者,早期ECMO辅助复苏可显著提高出院生存率,应考虑将此类患者快速转运至具备ECMO能力的中心。
- 标准ACLS组出院生存率仅7%,提示对难治性室颤患者标准ACLS效果有限,早期识别并启动ECMO评估可能改变预后。
- 该研究为单中心小样本2期试验,结果需多中心验证,不能外推至不符合纳入标准的人群(如年龄>75岁、非室颤心律、预计转运时间≥30分钟、未使用LUCAS)。
指南或共识出处
- ARREST trial, ClinicalTrials.gov NCT03880565, 发表于Lancet,由National Heart, Lung, and Blood Institute资助。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Among patients with out-of-hospital cardiac arrest (OHCA) and ventricular fibrillation, more than half present with refractory ventricular fibrillation unresponsive to initial standard advanced cardiac life support (ACLS) treatment. We did the first randomised clinical trial in the USA of extracorporeal membrane oxygenation (ECMO)-facilitated resuscitation versus standard ACLS treatment in patients with OHCA and refractory ventricular fibrillation.
METHODS: For this phase 2, single centre, open-label, adaptive, safety and efficacy randomised clinical trial, we included adults aged 18-75 years presenting to the University of Minnesota Medical Center (MN, USA) with OHCA and refractory ventricular fibrillation, no return of spontaneous circulation after three shocks, automated cardiopulmonary resuscitation with a Lund University Cardiac Arrest System, and estimated transfer time shorter than 30 min. Patients were randomly assigned to early ECMO-facilitated resuscitation or standard ACLS treatment on hospital arrival by use of a secure schedule generated with permuted blocks of randomly varying block sizes. Allocation concealment was achieved by use of a randomisation schedule that required scratching off an opaque layer to reveal assignment. The primary outcome was survival to hospital discharge. Secondary outcomes were safety, survival, and functional assessment at hospital discharge and at 3 months and 6 months after discharge. All analyses were done on an intention-to-treat basis. The study qualified for exception from informed consent (21 Code of Federal Regulations 50.24). The ARREST trial is registered with ClinicalTrials.gov, NCT03880565.
FINDINGS: Between Aug 8, 2019, and June 14, 2020, 36 patients were assessed for inclusion. After exclusion of six patients, 30 were randomly assigned to standard ACLS treatment (n=15) or to early ECMO-facilitated resuscitation (n=15). One patient in the ECMO-facilitated resuscitation group withdrew from the study before discharge. The mean age was 59 years (range 36-73), and 25 (83%) of 30 patients were men. Survival to hospital discharge was observed in one (7%) of 15 patients (95% credible interval 1·6-30·2) in the standard ACLS treatment group versus six (43%) of 14 patients (21·3-67·7) in the early ECMO-facilitated resuscitation group (risk difference 36·2%, 3·7-59·2; posterior probability of ECMO superiority 0·9861). The study was terminated at the first preplanned interim analysis by the National Heart, Lung, and Blood Institute after unanimous recommendation from the Data Safety Monitoring Board after enrolling 30 patients because the posterior probability of ECMO superiority exceeded the prespecified monitoring boundary. Cumulative 6-month survival was significantly better in the early ECMO group than in the standard ACLS group. No unanticipated serious adverse events were observed.
INTERPRETATION: Early ECMO-facilitated resuscitation for patients with OHCA and refractory ventricular fibrillation significantly improved survival to hospital discharge compared with standard ACLS treatment.
FUNDING: National Heart, Lung, and Blood Institute.
参考来源
- Yannopoulos D, Bartos J, Raveendran G, et al. Advanced reperfusion strategies for patients with out-of-hospital cardiac arrest and refractory ventricular fibrillation (ARREST): a phase 2, single centre, open-label, randomised controlled trial. Lancet. 2020. PMID: 33197396. doi:10.1016/S0140-6736(20)32338-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。